GSK and Lilly will launch diabetes drugs to inject once a week within this year
The two new diabetes drugs, that need to be administered once a week, will enter the Korean market.
According to the industry concerned on the 8th, GSK and Lilly are working to acquire domestic approvals for respective ‘Tanzeum (albiglutide)’ and ‘Trulicity (dulaglutide)’. It is expected that bo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
